coin-img-ETHETH-2.82%coin-img-BTCBTC-2.88%coin-img-SOLSOL-4.70%coin-img-XRPXRP-1.24%coin-img-USDCUSDC-0.04%coin-img-XAUTXAUT+1.59%coin-img-DOGEDOGE-0.40%coin-img-HYPEHYPE-7.85%coin-img-ETHETH-2.82%coin-img-BTCBTC-2.88%coin-img-SOLSOL-4.70%coin-img-XRPXRP-1.24%coin-img-USDCUSDC-0.04%coin-img-XAUTXAUT+1.59%coin-img-DOGEDOGE-0.40%coin-img-HYPEHYPE-7.85%coin-img-ETHETH-2.82%coin-img-BTCBTC-2.88%coin-img-SOLSOL-4.70%coin-img-XRPXRP-1.24%coin-img-USDCUSDC-0.04%coin-img-XAUTXAUT+1.59%coin-img-DOGEDOGE-0.40%coin-img-HYPEHYPE-7.85%coin-img-ETHETH-2.82%coin-img-BTCBTC-2.88%coin-img-SOLSOL-4.70%coin-img-XRPXRP-1.24%coin-img-USDCUSDC-0.04%coin-img-XAUTXAUT+1.59%coin-img-DOGEDOGE-0.40%coin-img-HYPEHYPE-7.85%
user-avatar
Tim Fries

Vanda (VNDA) Soars 41.84% Premarket on FDA Approval of BYSANTI for Bipolar I and Schizophrenia

On February 23, 2026, Vanda Pharmaceuticals shares surged to $8.17 in premarket trading, up 41.84% from the prior close after the FDA cleared its new drug BYSANTI for adult Bipolar I manic episodes and schizophrenia. The approval, Vanda's second since December 2025, extends patent protection to 2044 and supports plans for a commercial launch in Q3 2026, boosting sentiment around the company's growth prospects.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.